3015-17-6

Basic information

• Product Name: 2-AzaadaMantane hydrochloride
• Synonyms: 2-AzaadaMantane hydrochloride
• CAS NO: 3015-17-6
• Molecular Formula: C9H16ClN
• Molecular Weight: 173.68304
• Mol File: 3015-17-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-AzaadaMantane hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AzaadaMantane hydrochloride(3015-17-6)
• EPA Substance Registry System: 2-AzaadaMantane hydrochloride(3015-17-6)

Safety Data

• Hazardous Substances Data: 3015-17-6(Hazardous Substances Data)

Usage

Chemical compound

2-AzaadaMantane hydrochloride

Properties

antiviral, antiparkinsonian

Action

inhibits replication of influenza A and B, respiratory syncytial virus

Potential use

treating Parkinson's disease, increasing dopamine release in the brain

Investigated for

anticonvulsant effects, treatment of epilepsy
Versatile chemical with potential applications in medical treatment

Upstream product

• 23014-71-3 4-oxotricyclo [3.3.1.1^{3, 7}]dec-2-yl methanesulfonate 
• 56820-19-0 bicyclo<3.3.1>non-6-ene-3-endo-carboxylic acid 
• 700-58-3 2-Adamantanone 
• 88537-12-6 3-endo-methoxycarbonylaminobicyclo<3.3.1>non-6-ene 

Downstream Products

• 1389264-13-4 methyl 2-azatricyclo[3.3.1.1³'⁷]decane-5-carboxylate 
• 1448697-71-9 3-(1H-benzotriazol-1-yl)-1-(5-hydroxy-2-azatricyclo[3.3.1.1^3,7]dec-2-yl)-3-phenylpropan-1-one 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF

(I) Disclosed herein are compounds of formula I, and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof; and therapeutic uses of these compounds, which are inhibitors of rearranged during transfection (RET), potentially useful in the treatment of RET-associated diseases, such as RET-associated cancers.

DERIVATIVES OF AZA ADAMANTANE AND USES THEREOF

The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.